FDA has cleared Daré Bioscience’s IND for DARE-HPV, a fixed-dose lopinavir/ritonavir vaginal insert, enabling a Phase 2 study in women with persistent high-risk HPV infection. The program is backed by a $10 million ARPA-H contract, with $6.5 million received, and targets a space with no FDA-approved pharmacologic therapies.
The core move is a regulatory green light to test a localized, self-administered antiviral intended to eliminate the virus before cervical disease emerges. Daré plans to assess safety and antiviral activity in a Phase 2 trial starting in 2026. The formulation repurposes known antiretrovirals into a soft gel insert aimed at high-risk HPV types that drive nearly all cervical cancer, shifting intervention earlier in the care pathway now dominated by watchful waiting and surgical treatment of lesions.
Strategically, this is a focused bet on repurposing and delivery innovation to address an entrenched gap in women’s health. ARPA-H funding reduces capital pressure and aligns the program with federal interest in STI innovation and prevention. The scientific and regulatory tension sits in the evidentiary standard: spontaneous clearance rates in HPV are substantial, which raises the bar for demonstrating a clinically meaningful delta in viral clearance versus placebo, and for proving durability that translates into fewer procedures and less progression to CIN2+. With no prior approvals to lean on, endpoint selection and validation will be central. A virologic clearance endpoint is plausible, but regulators may push for lesion-related outcomes or extended follow-up to show impact on disease trajectory and procedural burden.
For sites and CROs, the operational footprint is attractive but nontrivial. OB/GYN and colposcopy practices are the natural network, and a home-administered insert opens the door to decentralized elements such as self-collection for HPV DNA testing and ePRO-based adherence capture. That brings logistics around sample integrity, central-lab genotyping for high-risk subtypes, and consistent definitions of persistence at baseline. Inclusion criteria that require documented persistence over time will affect screening ratios and timelines. Safety monitoring will need to capture local tolerability and any systemic exposure concerns inherent to ritonavir co-formulation, even if expected to be low with topical delivery. For vendors, this is an opportunity to support remote specimen workflows, adherence verification, and standardized colposcopic adjudication if lesion assessments are included.
Sponsors and regulators should view this as a test case for earlier pharmacologic intervention in HPV and, more broadly, for antiviral approaches against pathogens historically managed through surveillance and surgery. It also intersects with equity goals: reducing reliance on repeated clinic-based monitoring could address disparities in follow-up and access that contribute to cervical cancer outcomes. If the Phase 2 readout is positive, the field will need clarity on whether a virologic endpoint can anchor a registrational path or whether a subsequent outcomes-focused study is required.
What to watch next: the Phase 2 protocol’s definition of persistence, targeted HPV genotypes, primary endpoint timing and durability requirements, and the control strategy given spontaneous clearance. Powering assumptions will reveal the company’s view of effect size needed to move regulators. Manufacturing and CMC for the soft gel insert, IP position around the formulation, and the cadence of ARPA-H milestone funding are additional execution levers. A clean safety profile with a clear, durable virologic signal would position Daré to open regulator dialogue on a novel approval pathway; anything less may push development toward larger, longer studies that tie clearance to reductions in CIN2+ and procedural interventions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
